Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
6-K
Debt Issuance
confidence 95%
filed 2026-06-16
STMicroelectronics announces a US$1.5 billion dual-tranche offering of convertible bonds (2031 and 2033 tranches) and the early redemption of its 2027 Convertible Bonds. This is a material creation of new direct financial obligations through debt issuance, approved by both the managing board and supervisory board, with settlement expected June 23, 2026. The offering proceeds will be used for general corporate purposes including redemption of existing debt.
View raw filing on EDGAR →
6-K
Debt Issuance
confidence 95%
filed 2026-06-16
STMicroelectronics announced the pricing of a US$1.5 billion dual-tranche offering of senior unsecured convertible bonds (US$750 million due 2031 and US$750 million due 2033). This is a material creation of direct financial obligations. The press release explicitly states the pricing terms, conversion prices, maturity dates, and settlement date (June 23, 2026), and notes that proceeds will be used for general corporate purposes including early redemption of existing convertible bonds. This is a classic debt issuance disclosure.
View raw filing on EDGAR →
8-K
Bankruptcy Filing
confidence 95%
filed 2026-06-16
Item 1.01
Sleep Number Corporation has filed for Chapter 11 bankruptcy protection and entered into a debtor-in-possession (DIP) financing agreement providing $260 million in committed financing to support operations during the reorganization process.
View raw filing on EDGAR →
8-K
M&A activity
confidence 75%
filed 2026-06-16
Item 1.01
Rocket Companies closed a $1.5 billion debt offering ($900M 2031 Notes and $600M 2034 Notes) on June 16, 2026, pursuant to an Indenture with U.S. Bank Trust Company. While this is technically a debt issuance rather than a traditional M&A transaction, Item 1.01 encompasses "Entry into a Material Definitive Agreement," and the Indenture constitutes a material definitive agreement. The proceeds are earmarked for debt refinancing (repaying 2026 and 2028 Rocket Mortgage Notes), making this a material capital structure event. However, this is more accurately characterized as a debt financing event than M&A; the closest fit in the taxonomy is ma_activity given the materiality and the Item 1.01 classification, though other_material would also be defensible.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-16
Item 7.01
MSC Industrial announced a cash dividend of $0.87 per share declared by its Board of Directors. While dividend declarations are routine corporate actions, this disclosure is material to investors as it affects shareholder returns and capital allocation. The event does not fit neatly into the more specific taxonomy categories (it is neither an earnings release, executive change, M&A activity, nor a financial restatement), making "other_material" the most appropriate classification.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-06-16
Item 7.01
The filing discloses execution of an Agreement and Plan of Merger whereby Simulations Plus will merge with a subsidiary of Altaris, LLC, with the Company surviving as a wholly owned subsidiary of Parent. This constitutes a material acquisition/change of control transaction. The disclosure explicitly references the Merger Agreement and announces the transaction via press release, which is the hallmark of Item 1.01 (M&A activity), even though it is filed under Item 7.01 (Regulation FD Disclosure).
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-16
Item 7.01
SDG&E and SoCalGas filed 2028 General Rate Case applications with the CPUC on June 15, 2026, requesting revenue requirements of $3,760 million (SDG&E) and $5,096 million (SoCalGas) for the 2028 test year, with attrition adjustments through 2031. This is a material regulatory filing that affects authorized revenue recovery and rates, but does not fit neatly into the standard 8-K taxonomy categories. While regulatory decisions are inherently material to utility investors, this disclosure is primarily informational about a pending CPUC proceeding rather than a discrete event like a covenant breach, impairment, or M&A activity.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-16
Item 5.02
B. Scot Ebron was appointed to the office of President of Shore United Bank, N.A. on June 15, 2026, and simultaneously appointed to the Bank's Board of Directors. This is a material executive appointment of a named officer to a senior leadership position at the Company's wholly-owned subsidiary, affecting the organizational structure and governance of the registrant.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-06-16
Item 5.02
Urban One entered into a new employment agreement with CFO Peter D. Thompson establishing comprehensive compensatory arrangements including a $750,000 base salary, $333,333 signing bonus, annual performance bonuses up to $300,000, a $850,000 completion bonus contingent on remediation of material weaknesses, and stock-based compensation grants totaling over $1.8 million through January 6, 2029.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-16
Item 5.07
Urban One held its 2026 Annual Meeting of Stockholders on June 11, 2026, with voting results on the election of six directors (Terry L. Jones, Brian W. McNeill, Catherine L. Hughes, Alfred C. Liggins III, B. Doyle Mitchell Jr., and D. Geoffrey Armstrong), approval of the 2026 Equity and Performance Incentive Plan, and ratification of PricewaterhouseCoopers LLP as independent auditor.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-16
Item 5.07
Columbia Sportswear held its Annual Meeting of shareholders with 49.6 million shares (97% of outstanding) voted. Results included election of all 10 directors with strong majorities, ratification of Deloitte & Touche LLP as auditor, approval of executive compensation, approval of the Amended and Restated 2020 Stock Incentive Plan (increasing authorized equity from 4.5 million to 9 million shares), and rejection of a proxy access proposal.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-16
Item 5.07
This is a classic Item 5.07 disclosure reporting the results of Chipotle's 2026 annual meeting of shareholders held on June 11, 2026. The filing presents final voting tallies for three proposals: election of ten directors (all elected with strong majorities), advisory approval of executive compensation, and ratification of Ernst & Young LLP as independent auditor. These are material governance events that affect investor understanding of board composition and shareholder sentiment on compensation and audit oversight.
View raw filing on EDGAR →
6-K
M&A activity
confidence 75%
filed 2026-06-16
EX-99.1
Western Copper & Gold has entered into an amended and restated investor rights agreement with Mitsubishi Materials, extending the partnership through November 30, 2028, contingent on Mitsubishi Materials acquiring 1.2 million common shares through open market purchases to return its ownership to approximately 5%. This represents a material strategic transaction involving a significant shareholder's increased equity stake and formalized governance rights, affecting the registrant's capital structure and control relationships.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-16
Item 5.07
This Item 5.07 filing discloses the results of the June 12, 2026 annual meeting of shareholders, including voting outcomes on four proposals: election of three directors, advisory approval of executive compensation, frequency of future compensation votes, and amendment to the Articles of Incorporation regarding board size. The disclosure of shareholder vote results at an annual meeting is the textbook definition of Item 5.07 and the shareholder_vote_results event type.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-06-16
Item 7.01
The filing discloses the closing of Natural Gas Services Group's acquisition of Flatrock Compression Holdings LLC, announced via a conference call on June 15, 2026. Although filed under Item 7.01 (Regulation FD Disclosure) rather than the typical Item 1.01 or 2.01, the substance is a material acquisition completion that would materially affect a reasonable investor's assessment of the registrant's business and financial position.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-06-16
Item 2.01
Prestige Consumer Healthcare completed the acquisition of the Breathe Right® brand and related assets from Foundation Consumer Brands for $1.045 billion in cash on June 12, 2026, financed through a new Term Loan Credit Agreement with an additional $95 million draw available for the previously announced LaCorium Health acquisition expected to close in Q2 fiscal 2027.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-06-16
EX-99.1
This press release announces a significant order intake of more than €26 million since mid-May 2026, with year-to-date orders of approximately €43 million through June 15, 2026. The disclosure highlights material business development across multiple customers and regions (China, Taiwan, South Korea, Europe) for advanced PCB manufacturing equipment (InfinityLine Production Equipment for HDI-ML and mSAP applications). While this is a material operational and commercial milestone reflecting strong market momentum and customer investment, it does not fit the specific event categories of earnings release (no financial results), M&A activity, or other defined types. The order intake announcement is a discrete operational/commercial event material to investor assessment of the company's business trajectory and market position.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-06-16
Item 7.01
The filing discloses a proposed all-stock merger of equals between Huntsman Corporation and Olin Corporation pursuant to an Agreement and Plan of Merger entered into on June 15, 2026. This is a material acquisition/change of control transaction announced via joint press release on June 16, 2026, with detailed disclosure of the merger structure, regulatory filing plans, and shareholder approval requirements. The transaction clearly qualifies as M&A activity under Item 1.01 or 2.01 standards.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-06-16
Item 8.01
PTC Therapeutics announced the pricing of a $500 million convertible notes offering (with an additional $50 million option), which will result in shares of common stock issuable upon conversion. The notes are unregistered securities sold pursuant to an exemption from Securities Act registration. This is a material dilutive issuance that raises substantial capital and creates future equity dilution through conversion rights.
View raw filing on EDGAR →
6-K
Exec Compensation
confidence 95%
filed 2026-06-16
EX-99.2
Kanzhun granted 550,498 RSU share awards to 45 employees on June 15, 2026, pursuant to the Post-IPO Share Scheme, with vesting schedules ranging from 2–4 years, performance targets covering 84.87% of awards, and clawback provisions.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-16
Item 5.07
Palvella Therapeutics held its Annual Meeting on June 16, 2026, with stockholders voting on six proposals: election of three Class III directors (Jenkins, Davis, Doux), ratification of Ernst & Young LLP as independent auditor, advisory approval of named executive officer compensation, advisory frequency vote on compensation (approved annually), approval of an amendment to the 2024 Equity Incentive Plan increasing authorized shares by 750,000, and adjournment authority. All proposals passed.
View raw filing on EDGAR →
6-K
M&A activity
confidence 98%
filed 2026-06-16
EX-99.1
The exhibit announces completion of Fairfax's acquisition of Kennedy Wilson Holdings, Inc. for US$10.90 per share in cash pursuant to a Merger Agreement. This is a material acquisition transaction where Fairfax holds a majority economic interest in the acquired company, along with a US$1.3 billion term loan facility and a stand-by guarantee arrangement. The completion of a major M&A transaction is a core material event under Item 1.01/2.01 of the 8-K taxonomy.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-16
Item 8.01
The disclosure announces FDA acknowledgment of a BLA resubmission for ONS-5010 (bevacizumab-vikg) with a Class 1 review designation and a 60-day PDUFA goal date of July 29, 2026. This is a material regulatory milestone for a biopharmaceutical company's lead product candidate, but does not fit neatly into the more specific event categories (it is neither a final approval/denial, a going-concern issue, nor a material impairment). The event would affect a reasonable investor's assessment of the company's regulatory progress and near-term catalysts.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-06-16
Item 5.04
The filing discloses a blackout period triggered by the "previously announced acquisition of TopBuild Corp." pursuant to a merger agreement dated April 18, 2026, with QXO, Inc. and its subsidiaries. While Item 5.04 addresses the technical blackout notice requirement, the material event underlying this disclosure is the M&A activity—the proposed merger itself—which is explicitly referenced as the reason for the blackout period and would materially affect investor assessment of the company's future.
View raw filing on EDGAR →
6-K
M&A activity
confidence 95%
filed 2026-06-16
EX-99.1
The exhibit announces the completion of Nebius's acquisition of Eigen AI, a leading inference and model optimization company. The transaction was announced May 1, 2026, and closed June 10, 2026, following receipt of required regulatory approvals. This is a material acquisition completion that would affect a reasonable investor's assessment of the registrant's strategic direction and financial position.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 92%
filed 2026-06-16
EX-99.1
Biophytis announces temporary suspension of trading of its shares on Euronext Growth Paris effective June 15, 2026, due to non-publication of the annual financial report for fiscal year 2025. The suspension results from an "operational delay in the preparation of financial statements" and trading is expected to resume only after publication of the audited annual report (expected no later than end of July 2026). This is a material delisting risk event — a failure to satisfy continued listing requirements (timely filing of annual financial statements) that has triggered an exchange-imposed trading suspension, directly threatening the registrant's continued listing status.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-16
Item 5.07
This is a clear disclosure of shareholder voting results from Latch's June 10, 2026 annual meeting of stockholders, filed under Item 5.07. The filing presents tabulated voting outcomes for three proposals: election of six directors, ratification of BDO USA as independent auditor, and advisory approval of named executive officer compensation. All three proposals passed with substantial majorities, making this a routine but material shareholder governance disclosure.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-06-16
Item 8.01
The filing discloses that the HSR waiting period for the previously announced merger between Esperion and ArchiMed SAS (through Essence Parent Inc. and MergerCo) expired on June 15, 2026. This represents a material milestone in the completion of a change-of-control transaction, with the Company surviving as a wholly-owned subsidiary of Parent. The disclosure explicitly references the Merger Agreement entered into on May 1, 2026, and notes that stockholder approval remains a closing condition, with the special meeting scheduled for July 8, 2026.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-16
Item 5.07
This is a clear Item 5.07 disclosure of shareholder voting results from ExlService's 2026 Annual Meeting of Stockholders. The filing reports the final vote tallies for three proposals: election of seven board directors (all elected), ratification of Deloitte & Touche LLP as auditor (approved), and Say-on-Pay advisory vote (approved). The detailed voting results with For/Against/Abstain/Broker Non-Vote counts are the core content of the filing.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-06-16
The 6-K discloses the results of Ardmore Shipping's 2026 Annual Meeting of Shareholders held on June 15, 2026, reporting the election of three Class I Directors (Mats Berglund, Kirsi Tikka, and Gernot Ruppelt) with specific vote tallies for and withheld. This is a direct disclosure of shareholder vote results under Item 5.07 equivalent, which is material to investors as it reflects the composition of the board of directors.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 85%
filed 2026-06-16
Item 5.02
The disclosure centers on an Amended and Restated Employment Agreement with Chad Cowan, Ph.D., the Chief Scientific Officer, modifying his compensation structure to part-time status with a reduced annual salary of $296,150 and pro-rated performance-based bonus eligibility. While the agreement also addresses termination provisions, the principal disclosed action is a compensatory arrangement modification for a named executive officer, which falls squarely within exec_compensation rather than exec_departure (no departure occurred) or exec_appointment (no new role assumed).
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-16
Item 5.07
This is a clear disclosure of shareholder voting results from John Marshall Bancorp's Annual Meeting of Shareholders held on June 16, 2026. The filing reports the outcomes of two proposals: (1) election of eight directors with detailed vote tallies for each nominee, and (2) ratification of Yount, Hyde & Barbour, P.C. as the independent auditor. This is a quintessential Item 5.07 disclosure and is material to investors as it confirms the composition of the board and auditor appointment.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-06-16
Item 5.02
Shareholders approved an amended and restated 2013 Performance Incentive Plan that increases the share pool by 8.8 million shares (from 48.0 to 56.8 million) and extends the plan expiration to 2036, materially expanding equity award capacity for officers, directors, and employees.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-16
Item 5.07
Norwegian Cruise Line Holdings held its annual general meeting on June 11, 2026, with shareholders voting on six proposals including election of three Class I directors, advisory approval of executive compensation, auditor ratification, and approval of a board declassification proposal.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-06-16
Item 3.01
The filing discloses a delisting notice from Nasdaq under Item 3.01, specifically that MaxCyte's stock fell below the $1.00 minimum bid price requirement for 30 consecutive trading days, triggering non-compliance with Nasdaq Listing Rule 5450(a)(1). Although the company subsequently regained compliance by June 9, 2026, the initial delisting risk and the regulatory process itself are material events that would affect investor assessment of the company's listing status and market viability.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 35%
filed 2026-06-16
Item 8.01
Safehold Inc. disclosed a private placement of $225 million in Senior Notes under a note purchase agreement, offered in reliance on Section 4(a)(2) of the Securities Act without registration. While this is a debt issuance rather than an equity issuance, the unregistered nature and private placement structure align with the dilutive_issuance category's focus on unregistered securities sales. However, the event is fundamentally a debt financing, not an equity dilution, which creates genuine uncertainty about the best classification.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-16
Item 5.07
This Item 5.07 disclosure reports the results of the Annual Meeting of Shareholders held on June 11, 2026, including: (1) election of seven board members with vote tallies for each director; (2) non-binding advisory approval of named executive officer compensation (28,547,283 shares for); (3) shareholder approval of annual frequency for future say-on-pay votes; and (4) ratification of Ernst & Young LLP as independent auditor (29,842,514 shares for). These are standard shareholder vote results that materially inform investors about board composition and governance decisions.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-06-16
Item 2.01
Assertio Holdings completed a tender offer and merger on June 16, 2026, whereby the company became a wholly owned subsidiary of Parent. The transaction involved acceptance of 4,286,488 shares (66.32% of outstanding) in the tender offer, followed by a Section 251(h) merger converting all remaining shares into cash merger consideration, constituting a material change of control.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-06-16
Item 3.01
Assertio Holdings notified Nasdaq to halt trading and delist its shares effective June 16, 2026, in connection with the merger closing. The company intends to file Form 15 to terminate registration and suspend reporting obligations.
View raw filing on EDGAR →
8-K
Exec departure
confidence 75%
filed 2026-06-16
Item 5.02
Six directors (Heather L. Mason, Sravan K. Emany, Sigurd C. Kirk, William T. McKee, David M. Stark, and Mark L. Reisenauer) voluntarily resigned as directors, and all officers ceased service, in connection with the merger transaction.
View raw filing on EDGAR →
8-K
Covenant Breach
confidence 65%
filed 2026-06-16
Item 2.04
The merger triggered a Fundamental Change and Make-Whole Fundamental Change under the company's convertible notes indenture, accelerating conversion rights and granting noteholders repurchase rights at 100% of principal plus accrued interest on $40 million in convertible notes.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-16
Item 5.03
The Company's certificate of incorporation and bylaws were completely amended and restated pursuant to the terms of the Merger Agreement at the Effective Time, reflecting the completed merger transaction.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-16
Item 5.07
This Item 5.07 filing discloses the results of Battalion Oil Corporation's June 11, 2026 Annual Meeting of Stockholders, including voting outcomes for two proposals: election of four directors (Jonathan D. Barrett, Gregory S. Hinds, William D. Rogers, and Matthew B. Steele) and ratification of Deloitte & Touche LLP as independent auditor. The tabulated vote counts for each proposal are the core disclosure, making this a classic shareholder_vote_results event.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-16
Item 5.07
Elutia Inc. held its annual meeting of stockholders on June 11, 2026, at which shareholders voted on five proposals: election of two Class III directors (David Colpman and Kevin Rakin), ratification of PricewaterhouseCoopers LLP as auditor, approval of the First Amendment to the 2020 Incentive Award Plan, advisory approval of named executive officer compensation, and advisory vote on say-on-pay frequency. All five proposals passed.
View raw filing on EDGAR →
8-K
M&A activity
confidence 97%
filed 2026-06-16
Item 1.01
Huntsman Corporation entered into an Agreement and Plan of Merger with Olin Corporation on June 15, 2026, providing for an all-stock merger of equals transaction at an exchange ratio of 0.5476 shares of Olin Common Stock per Huntsman share. The filing also discloses a concurrent voting and support agreement executed by Peter Huntsman and affiliated entities to vote their shares in favor of the merger and against competing proposals.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-16
Item 5.07
This 8-K Item 5.07 discloses the final results of Adagio Medical's 2026 Annual Meeting of Stockholders held on June 16, 2026, including voting outcomes for two proposals: election of two directors (Orly Mishan and Sean Salmon, both elected) and ratification of WithumSmith+Brown, PC as independent auditor (ratified with overwhelming support). The disclosure provides vote counts, shares outstanding, and quorum information, which is the standard format for shareholder vote results required under Item 5.07.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-16
Item 1.01
Antero Resources established a $1.65 billion commercial paper program on June 16, 2026, creating a material direct financial obligation. The program includes dealer agreements and is intended for general corporate purposes including acquisitions and debt repayment, representing a significant financing commitment affecting the company's liquidity and capital structure.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-16
Item 8.01
The disclosure announces a new patent related to manufacturing of pelareorep and updates to the intellectual property portfolio. For a biotech company, patent issuance and IP portfolio strengthening can be material to investors assessing competitive position and product protection, though the filing provides limited detail on the patent's scope or commercial significance. This does not fit neatly into the more specific event categories (not earnings, litigation, impairment, etc.), warranting classification as other_material.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-16
Item 5.07
This Item 5.07 disclosure reports the final voting results from Gyre Therapeutics' June 10, 2026 Annual Meeting of Stockholders, including election of directors (David M. Epstein and Dan Weng), non-binding advisory vote on executive compensation, ratification of Grant Thornton Zhitong as independent auditor, and approval of Series B Preferred Stock conversion. The filing presents tabulated vote counts for each proposal, which is the core content of a shareholder_vote_results event.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 92%
filed 2026-06-16
Item 8.01
The filing discloses three lawsuits challenging the proposed merger transaction filed in New York Supreme Court (Phillips v. Green Dot, Richardson v. Green Dot, and Zaccagnino v. Brewster), plus demand letters from purported stockholders alleging disclosure deficiencies in the proxy statement/prospectus. Although the company denies merit and made supplemental disclosures to mitigate litigation risk, the existence of multiple shareholder class-action-style challenges to a material M&A transaction constitutes material litigation that would affect a reasonable investor's assessment of transaction risk and timing.
View raw filing on EDGAR →